Pharmacokinetic Simulation Of Tenax's Oral Levosimendan Suggests Higher Drug Exposure Than IV Dosing In PH-HFpEF

A computational five-compartment pharmacokinetic model built on published parameters suggests that daily oral levosimendan delivers higher and substantially more stable free drug exposure than the weekly IV infusions behind the significant 6MWD improvement in Phase 2.